While the definition of hypertrophic cardiomyopathy (HCM) primarily focuses on left ventricular (LV) involvement, sarcomeric mutations cause similar myopathic abnormalities in both ventricles, with right ventricular (RV) hypertrophy being present in a significant number of cases. To a limited extent, the hypertro...
A. Clement, L. Badano, V. Rella et al.· European Heart Journal· 0 citations
Cardiovascular disease is the leading cause of morbidity and mortality in chronic kidney disease (CKD). Structural remodelling, left ventricular hypertrophy, diastolic dysfunction, and right heart abnormalities are common even in moderate CKD stages and reflect complex cardio–renal interactions. Serum biomarkers...
M. Covic, A. Stefan, G. Dodi et al.· European Heart Journal· 0 citations
In patients with moderate-to-advanced CKD, previously unrecognised HFpEF was identified in approximately half of participants using guideline-based diagnostic criteria, supporting its role as a rule-in rather than rule-out tool in CKD.
M. Covic, A. Stefan, G. Dodi et al.· European Heart Journal· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.